Eurobiomed is pleased to invite you to the 3rd edition of Immunology Days, to be held at the EMD in Marseille. Under the theme “ All committed to the development of immune therapies against cancer, inflammatory and infectious diseases ”, this year’s event will bring together key players from research and industry to advance innovations in immunology. This unique event offers a space dedicated to exchanging knowledge and sharing scientific advances in the field of immunology. Participants will be able to attend presentations of innovative projects and discover new perspectives on immune therapies, all in a setting conducive to scientific interaction.
PROGRAM
Welcome - Coffee
Introduction
Emilie ROYERE - Directrice Générale, Eurobiomed
Words from local authorities
Mme Emmanuelle CHARAFE - Vice-présidente de la Métropole déléguée à la Santé, à l’Enseignement supérieur et la Recherche, à la Recherche médicale, à l’économie de la santé.
An update : MIB, an International Biocluster in Immunology
Pr Daniel OLIVE - MD PhD, Aix-Marseille Université
Part 1: Ambition to accelerate, target discovery, validation and success
Validating the Functional Characteristics of Live Immune Cells at a Single-Cell Level through Beacon,
M. Tiago SANTOS - Market Development Executive, Bruker Cellular Analysis
Harnessing the potential of CAR-T cell therapy through new cellular engineering and models
Pr. Bernard MALISSEN – Directeur Emérite de Recherche CNRS, Ancien Directeur du CIML, Ancien Directeur et Fondateur du CIPHE
C2IT, When IPC and APHM join forces to reinforce clinical trials in immunology
Pr Norbert VEY - Managing Director, Institut Paoli-Calmettes & Emilie GARRIDO PRADALIE - Directrice Recherche en Santé et Maladies Rares, Assistance Publique - Hôpitaux de Marseille
Challenges and opportunities for the development of prospective cohorts in autoimmune diseases: a case study in lupus and vasculitis,
Pr. Noémie Jourde-Chiche - MD, PhD - Aix-Marseille Université, Assistance Publique - Hôpitaux de Marseille - Hôpital de la Conception
12h20 : Lunch and Networking
Key Note : Sanofi, a global strategy to target immune-diseases,
Mr. Frédéric MARRACHE - VP -Global Project Head - Clinical Development - Immunology and Inflammation Therapeutic Area, SANOFI
Part 2: A hub for industrial innovation from discovery to industrialization
Remora Biotech Venture Builder : new generation of first-in class and multifunctional immunotherapy products to treat cancer and AID
Mr. David BECHARD- PhD CEO, Remora Biotech France – Nanomunity – Radiomune Pharma
Antibody discovery and repertoire analysis using single cell Beacon technology,
Pr. François ROMAGNE - Scientific Director, MImAbs
ICT01 in combination with venetoclax & azacitidine : from preclinical PoC to Phase 1 interim results,
Aude de Gassart, VP Développement préclinique - Imcheck Thérapeutique
New opportunities for democratizing the use of flow cytometry
Mr. Fabrice MALERGUE- PhD Senior Staff Research Scientist, Beckman Coulter Life Sciences/ Immunotech
Networking
End
About MIB
Located at the center of Marseille, home of immunology research for over 40 years, the mission of MIB is to develop and implement cooperation between all stakeholders of tomorrow’s immunology at the national and international levels. Researchers, hospital practitioners, biotechs & pharma innovators, investors, students and public authorities will benefit from a dynamic environment (technology platforms, immunology start-up studios, support for SMEs and larger companies, etc.) and complementary expertise to develop cutting-edge immune-based therapies and new diagnostic tools. With a budget of €97 million as part of the France 2030 Plan, MIB aims to accelerate translational research in immunology, focusing on four therapeutic areas: oncology, infectiology, autoimmune and inflammatory diseases, for the benefit of patients.
MIB partners :
During this event you will have a table for the dispositif Move2Digital
